Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 400 participants.
Also called NCT02596555
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Prof. Stavros Konstantinides, MD
- Registry
-
NCT02596555
-
- Other papers using this trial's data
- Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Terminated
Technical summary
Registry record NCT02596555. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01 (actual); primary completion 2020-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
- Acronym
- PEITHO-2
- Condition
- Pulmonary Embolism
- Intervention (Drug)
- Dabigatran
- Lead sponsor
- Prof. Stavros Konstantinides, MD
- Collaborator
- European Georges Pompidou Hospital
Record details
- Record id
cardio:ct-nct02596555- Content hash
a978b4476539b52d5e741071db43b0d938e3d537b7d25614681dcd37c51d5782